Extract

The primary objective is to assess the efficacy of 2 fixed doses of rimonabant versus placebo on abstinence from tobacco use in cigarette smokers. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period and to observe the percentage of abstinent subjects during a 40-week follow-up post treatment.

Inclusion criteria

• SMOKING CESSATION

Country

• Belgium
• Denmark
• France
• Spain
• Sweden
• Switzerland
• United Kingdom

Links

• ictrp
• nct